New Zealand markets closed

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.0500-0.0500 (-1.61%)
At close: 04:00PM EDT
3.0600 +0.01 (+0.33%)
After hours: 06:48PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 459.49M
Enterprise value 567.14M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)3.37
Price/book (mrq)12.60
Enterprise value/revenue 4.29
Enterprise value/EBITDA -1.55

Trading information

Stock price history

Beta (5Y monthly) 1.81
52-week change 383.73%
S&P500 52-week change 318.96%
52-week high 33.9300
52-week low 30.5000
50-day moving average 33.3386
200-day moving average 32.3526

Share statistics

Avg vol (3-month) 32.36M
Avg vol (10-day) 32.07M
Shares outstanding 5150.65M
Implied shares outstanding 6150.65M
Float 8112.21M
% held by insiders 10.72%
% held by institutions 180.66%
Shares short (15 Jul 2024) 435.66M
Short ratio (15 Jul 2024) 413.49
Short % of float (15 Jul 2024) 430.66%
Short % of shares outstanding (15 Jul 2024) 423.67%
Shares short (prior month 14 Jun 2024) 430.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 313 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -61.28%
Operating margin (ttm)-13.84%

Management effectiveness

Return on assets (ttm)-18.45%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)132.1M
Revenue per share (ttm)0.90
Quarterly revenue growth (yoy)17.10%
Gross profit (ttm)N/A
EBITDA -61.88M
Net income avi to common (ttm)-80.95M
Diluted EPS (ttm)-0.5500
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)71.52M
Total cash per share (mrq)0.47
Total debt (mrq)179.17M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.47
Book value per share (mrq)-0.22

Cash flow statement

Operating cash flow (ttm)-43.41M
Levered free cash flow (ttm)-11.77M